



## Author index

Volume 39 (1995)

- Adinoff, B. 39, 69  
Ball, D.M. 39, 181  
Bauer, L.O. 39, 213  
Belding, M.A. 39, 45  
Bigelow, G.E. 39, 55, 91  
Blackson, T. 39, 253  
Borzellica, J.F. 39, 83  
Brady, K.T. 39, 69  
Brauer, L.H. 39, 223  
Brigham, J. 39, 253  
Brooner, R.K. 39, 91  
Caprara, G.V. 39, 253  
Chami, T.N. 39, 151  
Charney, D.S. 39, 245  
Cheskin, L.J. 39, 151  
Chou, P.S. 39, 37  
Darke, S. 39, 231  
Davies, J.B. 39, 237  
Dawe, S. 39, 207  
Dawson, D.A. 39, 37  
de Wit, H. 39, 223  
Fassos, F.F. 39, 1  
Feigelman, W. 39, 75  
Feingold, A. 39, 99  
Garner, J.E. 39, 55  
Gibb, R. 39, 181  
Ginn, D.H. 39, 55  
González-Reimers, E. 39, 23  
Gossop, M. 39, 7  
Grant, B.F. 39, 37, 197  
Gray, J.A. 39, 207  
Greenfield, L. 39, 91  
Griffiths, R.R. 39, 167  
Gruss, T. 39, 33  
Haberny, K.A. 39, 55  
Hall, W. 39, 231  
Handelsman, L. 39, 173  
Harford, T.C. 39, 37, 197  
Hersh, D. 39, 213  
Hillman, A. 39, 181  
Hsieh, Y.-C. 39, 15  
Iguchi, M.Y. 39, 45  
Jaffe, J.H. 39, 151  
Jing, X. 39, 63  
Johnson, R.E. 39, 151  
Kidorf, M. 39, 167  
Klein, D.F. 39, 185  
Kleinman, P.H. 39, 75  
Koenig, T. 39, 185  
Kosten, T.R. 39, 245  
Kranzler, H.R. 39, 213  
Krystal, J.H. 39, 245  
LaBuda, M.C. 39, 129  
Lakin, M. 39, 45  
Lamb, R.J. 39, 45  
Langenbucher, J.W. 39, 139  
Lesieur, H.R. 39, 75  
Lesser, M.L. 39, 75  
Lichtman, A.H. 39, 83  
Limpitlaw, L. 39, 173  
Macpherson, A. 39, 237  
Malcolm, R. 39, 69  
Maludzińska, E. 39, 33  
Martínez-Riera, A. 39, 23  
McBride, A.J. 39, 29  
McGrath, P.J. 39, 185  
McGue, M. 39, 129  
Mezzich, A.C. 39, 15  
Milena-Abril, A. 39, 23  
Miller, K.J. 39, 139  
Millman, R.B. 39, 75  
Moore, K.A. 39, 83  
Morgenstern, J. 39, 139  
Moss, H. 39, 253  
Mucha, R.F. 39, 1  
Murray, R. 39, 181  
Nunes, E.V. 39, 185  
Ocepek-Welikson, K. 39, 185  
Oramas-Rodríguez, J. 39, 23  
Paris, P. 39, 173  
Parks, S.M. 39, 15  
Perl, F.M. 39, 1  
Peters, T. 39, 181  
Pickens, R.W. 39, 129  
Pickering, R.P. 39, 37  
Poklis, A. 39, 83  
Powell, J.F. 39, 181  
Quitkin, F.M. 39, 185  
Randall, C.L. 39, 69  
Reid, M.M. 39, 237  
Rodríguez-Moreno, F. 39, 23  
Rodríguez-Rodríguez, E. 39, 23  
Ross, H.E. 39, 111  
Rounsville, B. 39, 99  
Rukstalis, M.R. 39, 223  
Rybakowski, J. 39, 33  
Santolaria-Fernández, F. 39, 23  
Schmeidler, J. 39, 173  
Setoda, D. 39, 55  
Sherman, D. 39, 181  
Shewan, D. 39, 237  
Sloan, J.W. 39, 63  
Smith, I. 39, 181  
Sonne, S. 39, 69  
Stewart, J.W. 39, 185  
Stimmel, B. 39, 173  
Stine, S.M. 39, 245  
Stitzer, M.L. 39, 167  
Svikis, D.S. 39, 129  
Tarter, R.E. 39, 15, 253  
Terry, R. 39, 45  
Volpicelli, J.R. 39, 33  
Wager, S. 39, 185  
Wala, E.P. 39, 63  
Walsh, S.L. 39, 55  
Wilkins, J.N. 39, 55  
Williams, D. 39, 173  
Ziółkowski, M. 39, 33





## Subject index

Volume 39 (1995)

**Abuse criteria; DSM-IV; Diagnostic criteria; Quantitative model; Qualitative model; Substance abuse** 39, 99

**Adolescence; Neuropsychology; Drug abuse; Alcoholism; Female** 39, 15

**Alcohol abuse; Cocaine dependence; Psychopathology; Polysubstance abuse** 39, 69

**Alcohol abuse/dependence; Epidemiology; Comorbidity; Psychiatric disorders; Risk factors** 39, 111

**Alcohol dependence; Alcohol tolerance** 39, 33

**Alcohol dependence syndrome; Cytochrome P450IIIE1; Genes; Cirrhosis; Korsakoff's syndrome** 39, 181

**Alcohol tolerance; Alcohol dependence** 39, 33

**Alcohol use disorders; Comorbidity; Major depression; Comorbid disorder** 39, 197

**Alcoholic hepatitis; Interleukin;  $\gamma$ -Interferon; Tumor necrosis factor; Cytokines** 39, 23

**Alcoholism; Diagnosis; Drug abuse; DSM-III; DSM-IV; ICD-10; Severity; Validity** 39, 139

**Alcoholism; Genetics; Comorbidity; Twins; Drug abuse; Mental disorders** 39, 129

**Alcoholism; Neuropsychology; Adolescence; Drug abuse; Female** 39, 15

**Amantadine; Cocaine dependence; Methadone maintenance; Dopamine agonist; Clinical trial** 39, 173

**Ampphetamines; Polydrug use; Heroin** 39, 231

**Behavior therapy; Contingency management; Methadone maintenance** 39, 167

**Cannabis; Clinic attenders; Cannabis and the law** 39, 29

**Cannabis and the law; Cannabis; Clinic attenders** 39, 29

**Carbamazepine; Cocaine; Craving; Cue reactivity; EEG** 39, 213

**Cardiovascular; Selegiline;  $\beta$ -Deprenyl; Cocaine; Safety; Subjective** 39, 55

**Child development; Drug abuse; Etiology; Event related potential; Family; Dysfunction** 39, 253

**Cirrhosis; Cytochrome P450IIIE1; Genes; Korsakoff's syndrome; Alcohol dependence syndrome** 39, 181

**Clinic attenders; Cannabis; Cannabis and the law** 39, 29

**Clinical trial; Cocaine dependence; Methadone maintenance; Amantadine; Dopamine agonist** 39, 173

**Clonidine; Craving; Reinforcement; Opiate addiction; Humans; Methadone** 39, 207

**Cocaine; Carbamazepine; Craving; Cue reactivity; EEG** 39, 213

**Cocaine; Pharmacotherapy; Depression; Imipramine; Desipramine** 39, 185

**Cocaine; Selegiline;  $\beta$ -Deprenyl; Safety; Cardiovascular; Subjective** 39, 55

**Cocaine abuse; Treatment; Mazindol** 39, 245

**Cocaine dependence; Methadone maintenance; Amantadine; Dopamine agonist; Clinical trial** 39, 173

**Cocaine dependence; Psychopathology; Alcohol abuse; Polysubstance abuse** 39, 69

**Comorbid disorder; Comorbidity; Alcohol use disorders; Major depression** 39, 197

**Comorbidity; Alcohol use disorders; Major depression; Comorbid disorder** 39, 197

**Comorbidity; Epidemiology; Alcohol abuse/dependence; Psychiatric disorders; Risk factors** 39, 111

**Comorbidity; Genetics; Twins; Alcoholism; Drug abuse; Mental disorders** 39, 129

**Conditioned aversion; Valproate; Pentylenetetrazole; Withdrawal discomfort; Quasi-withdrawal; Naloxone** 39, 1

**Constipation; Opioid antagonists; Opioids; Nalmefene** 39, 151

**Contingency management; Behavior therapy; Methadone maintenance** 39, 167

- Craving;** Carbamazepine; Cocaine; Cue reactivity; EEG 39, 213
- Craving;** Reinforcement; Opiate addiction; Humans; Methadone; Clonidine 39, 207
- Cue reactivity;** Carbamazepine; Cocaine; Craving; EEG 39, 213
- Cytochrome P450IIIE1;** Genes; Cirrhosis; Korsakoff's syndrome; Alcohol dependence syndrome 39, 181
- Cytokines;** Alcoholic hepatitis; Interleukin;  $\gamma$ -Interferon; Tumor necrosis factor 39, 23
- d-Amphetamine;** Paroxetine; Subjective effects; Serotonin; Healthy volunteers 39, 223
- Depression;** Cocaine; Pharmacotherapy; Imipramine; Desipramine 39, 185
- Desipramine;** Cocaine; Pharmacotherapy; Depression; Imipramine 39, 185
- Diagnosis;** Alcoholism; Drug abuse; DSM-III; DSM-IV; ICD-10; Severity; Validity 39, 139
- Diagnostic criteria;** DSM-IV; Abuse criteria; Quantitative model; Qualitative model; Substance abuse 39, 99
- Diagnostic interview;** Reliability; Diagnostic reliability; Psychiatric assessment; Test-retest 39, 37
- Diagnostic reliability;** Reliability; Psychiatric assessment; Diagnostic interview; Test-retest 39, 37
- Diazepam dependence in rat;** Flunitrazepam dependence in rat; Nordiazepam dependence in rat; Slow-release of benzodiazepines; Flumazenil; Precipitated abstinence 39, 63
- Dopamine agonist;** Cocaine dependence; Methadone maintenance; Amantadine; Clinical trial 39, 173
- Drug abuse;** Alcoholism; Diagnosis; DSM-III; DSM-IV; ICD-10; Severity; Validity 39, 139
- Drug abuse;** Etiology; Event related potential; Family; Dysfunction; Child development 39, 253
- Drug abuse;** Genetics; Comorbidity; Twins; Alcoholism; Mental disorders 39, 129
- Drug abuse;** Neuropsychology; Adolescence; Alcoholism; Female 39, 15
- Drug Reduction Programme;** Injection; Sharing of equipment; Scottish prisons; HIV risk 39, 237
- DSM-III;** Alcoholism; Diagnosis; Drug abuse; DSM-IV; ICD-10; Severity; Validity 39, 139
- DSM-IV;** Abuse criteria; Diagnostic criteria; Quantitative model; Qualitative model; Substance abuse 39, 99
- DSM-IV;** Alcoholism; Diagnosis; Drug abuse; DSM-III; ICD-10; Severity; Validity 39, 139
- Dysfunction;** Drug abuse; Etiology; Event related potential; Family; Child development 39, 253
- EEG;** Carbamazepine; Cocaine; Craving; Cue reactivity 39, 213
- Epidemiology;** Alcohol abuse/dependence; Comorbidity; Psychiatric disorders; Risk factors 39, 111
- Etiology;** Drug abuse; Event related potential; Family; Dysfunction; Child development 39, 253
- Event related potential;** Drug abuse; Etiology; Family; Dysfunction; Child development 39, 253
- Family;** Drug abuse; Etiology; Event related potential; Dysfunction; Child development 39, 253
- Female;** Neuropsychology; Adolescence; Drug abuse; Alcoholism 39, 15
- Flumazenil;** Flunitrazepam dependence in rat; Nordiazepam dependence in rat; Diazepam dependence in rat; Slow-release of benzodiazepines; Precipitated abstinence 39, 63
- Flunitrazepam dependence in rat;** Nordiazepam dependence in rat; Diazepam dependence in rat; Slow-release of benzodiazepines; Flumazenil; Precipitated abstinence 39, 63
- $\gamma$ -Interferon;** Alcoholic hepatitis; Interleukin; Tumor necrosis factor; Cytokines 39, 23
- Genes;** Cytochrome P450IIIE1; Cirrhosis; Korsakoff's syndrome; Alcohol dependence syndrome 39, 181
- Genetics;** Comorbidity; Twins; Alcoholism; Drug abuse; Mental disorders 39, 129
- Health care services;** Treatment services; WHO, International survey 39, 7
- Healthy volunteers;** Paroxetine; d-Amphetamine; Subjective effects; Serotonin 39, 223
- Heroin;** Methadone; Stages-of-change; Treatment readiness 39, 45
- Heroin;** Polydrug use; Amphetamines 39, 231
- HIV risk;** Injection; Sharing of equipment; Scottish prisons; Drug Reduction Programme 39, 237
- HIV-I;** Intravenous drug use; Injection; Needle sharing; Urinalysis; Self-report; Validity 39, 91
- Humans;** Craving; Reinforcement; Opiate addiction; Methadone; Clonidine 39, 207
- ICD-10;** Alcoholism; Diagnosis; Drug abuse; DSM-III; DSM-IV; Severity; Validity 39, 139
- Imipramine;** Cocaine; Pharmacotherapy; Depression; Desipramine 39, 185
- Injection;** Intravenous drug use; Needle sharing; Urinalysis; Self-report; Validity; HIV-I 39, 91

- Injection;** Sharing of equipment; Scottish prisons; HIV risk; Drug Reduction Programme 39, 237
- Interleukin;** Alcoholic hepatitis;  $\gamma$ -Interferon; Tumor necrosis factor; Cytokines 39, 23
- Intravenous drug use;** Injection; Needle sharing; Urinalysis; Self-report; Validity; HIV-1 39, 91
- Korsakoff's syndrome;** Cytochrome P450IIIE1; Genes; Cirrhosis; Alcohol dependence syndrome 39, 181
- $\beta$ -Deprenyl;** Selegiline; Cocaine; Safety; Cardiovascular; Subjective 39, 55
- Major depression;** Comorbidity; Alcohol use disorders; Comorbid disorder 39, 197
- Mazindol;** Cocaine abuse; Treatment 39, 245
- Mental disorders;** Genetics; Comorbidity; Twins; Alcoholism; Drug abuse 39, 129
- Methadone;** Craving; Reinforcement; Opiate addiction; Humans; Clonidine 39, 207
- Methadone;** Stages-of-change; Heroin; Treatment readiness 39, 45
- Methadone maintenance;** Cocaine dependence; Amantadine; Dopamine agonist; Clinical trial 39, 173
- Methadone maintenance;** Contingency management; Behavior therapy 39, 167
- Methadone treatment;** Problem gambling; Opiate addiction 39, 75
- Methamphetamine;** Methamphetamine impurities; Pharmacological activity; Pharmacological interactions 39, 83
- Methamphetamine impurities;** Methamphetamine; Pharmacological activity; Pharmacological interactions 39, 83
- Nalmefene;** Opioid antagonists; Constipation; Opioids 39, 151
- Naloxone;** Valproate; Pentylenetetrazol; Conditioned aversion; Withdrawal discomfort; Quasi-withdrawal 39, 1
- Needle sharing;** Intravenous drug use; Injection; Urinalysis; Self-report; Validity; HIV-1 39, 91
- Neuropsychology;** Adolescence; Drug abuse; Alcoholism; Female 39, 15
- Nordiazepam dependence in rat;** Flunitrazepam dependence in rat; Diazepam dependence in rat; Slow-release of benzodiazepines; Flumazenil; Precipitated abstinence 39, 63
- Opiate addiction;** Craving; Reinforcement; Humans; Methadone; Clonidine 39, 207
- Opiate addiction;** Problem gambling; Methadone treatment 39, 75
- Opioid antagonists;** Constipation; Opioids; Nalmefene 39, 151
- Opioids;** Opioid antagonists; Constipation; Nalmefene 39, 151
- Paroxetine;**  $d$ -Amphetamine; Subjective effects; Serotonin; Healthy volunteers 39, 223
- Pentylenetetrazol;** Valproate; Conditioned aversion; Withdrawal discomfort; Quasi-withdrawal; Naloxone 39, 1
- Pharmacological activity;** Methamphetamine; Methamphetamine impurities; Pharmacological interactions 39, 83
- Pharmacological interactions;** Methamphetamine; Methamphetamine impurities; Pharmacological activity 39, 83
- Pharmacotherapy;** Cocaine; Depression; Imipramine; Desipramine 39, 185
- Polydrug use;** Heroin; Amphetamines 39, 231
- Polysubstance abuse;** Cocaine dependence; Psychopathology; Alcohol abuse 39, 69
- Precipitated abstinence;** Flunitrazepam dependence in rat; Nordiazepam dependence in rat; Diazepam dependence in rat; Slow-release of benzodiazepines; Flumazenil 39, 63
- Problem gambling;** Opiate addiction; Methadone treatment 39, 75
- Psychiatric assessment;** Reliability; Diagnostic reliability; Diagnostic interview; Test-retest 39, 37
- Psychiatric disorders;** Epidemiology; Alcohol abuse/dependence; Comorbidity; Risk factors 39, 111
- Psychopathology;** Cocaine dependence; Alcohol abuse; Polysubstance abuse 39, 69
- Qualitative model;** DSM-IV; Abuse criteria; Diagnostic criteria; Quantitative model; Substance abuse 39, 99
- Quantitative model;** DSM-IV; Abuse criteria; Diagnostic criteria; Qualitative model; Substance abuse 39, 99
- Quasi-withdrawal;** Valproate; Pentylenetetrazol; Conditioned aversion; Withdrawal discomfort; Naloxone 39, 1
- Reinforcement;** Craving; Opiate addiction; Humans; Methadone; Clonidine 39, 207
- Reliability;** Diagnostic reliability; Psychiatric assessment; Diagnostic interview; Test-retest 39, 37
- Risk factors;** Epidemiology; Alcohol abuse/dependence; Comorbidity; Psychiatric disorders 39, 111
- Safety;** Selegiline;  $\beta$ -Deprenyl; Cocaine; Cardiovascular; Subjective 39, 55
- Scottish prisons;** Injection; Sharing of equipment; HIV risk; Drug Reduction Programme 39, 237
- Selegiline;**  $\beta$ -Deprenyl; Cocaine; Safety; Cardiovascular; Subjective 39, 55
- Self-report;** Intravenous drug use; Injection; Needle sharing; Urinalysis; Validity; HIV-1 39, 91
- Serotonin;** Paroxetine;  $d$ -Amphetamine; Subjective effects; Healthy volunteers 39, 223
- Severity;** Alcoholism; Diagnosis; Drug abuse; DSM-III; DSM-IV; ICD-10; Validity 39, 139

- Sharing of equipment;** Injection; Scottish prisons; HIV risk; Drug Reduction Programme 39, 237
- Slow-release of benzodiazepines;** Flunitrazepam dependence in rat; Nordiazepam dependence in rat; Diazepam dependence in rat; Flumazenil; Precipitated abstinence 39, 63
- Stages-of-change;** Methadone; Heroin; Treatment readiness 39, 45
- Subjective;** Selegiline; *L*-Deprenyl; Cocaine; Safety; Cardiovascular 39, 55
- Subjective effects;** Paroxetine; *d*-Amphetamine; Serotonin; Healthy volunteers 39, 223
- Substance abuse;** DSM-IV; Abuse criteria; Diagnostic criteria; Quantitative model; Qualitative model 39, 99
- Test-retest;** Reliability; Diagnostic reliability; Psychiatric assessment; Diagnostic interview 39, 37
- Treatment;** Cocaine abuse; Mazindol 39, 245
- Treatment readiness;** Methadone; Stages-of-change; Heroin 39, 45
- Treatment services;** WHO, International survey; Health care services 39, 7
- Tumor necrosis factor;** Alcoholic hepatitis; Interleukin;  $\gamma$ -Interferon; Cytokines 39, 23
- Twins;** Genetics; Comorbidity; Alcoholism; Drug abuse; Mental disorders 39, 129
- Urinalysis;** Intravenous drug use; Injection; Needle sharing; Self-report; Validity; HIV-1 39, 91
- Validity;** Alcoholism; Diagnosis; Drug abuse; DSM-III; DSM-IV; ICD-10; Severity 39, 139
- Validity;** Intravenous drug use; Injection; Needle sharing; Urinalysis; Self-report; HIV-1 39, 91
- Valproate;** Pentylenetetrazol; Conditioned aversion; Withdrawal discomfort; Quasi-withdrawal; Naloxone 39, 1
- WHO, International survey;** Treatment services; Health care services 39, 7
- Withdrawal discomfort;** Valproate; Pentylenetetrazol; Conditioned aversion; Quasi-withdrawal; Naloxone 39, 1

